This is read by an automated voice. Please report any issues or inconsistencies here. Bispecific antibodies offer immediate availability from a hospital pharmacy, circumventing the delays associated ...

The US Food and Drug Administration (FDA) outlined its thinking on what sponsors should consider when submitting premarket applications for chimeric antigen receptor (CAR) T cell products, including ...

We have curated a list of in vivo CAR T biotech companies in preclinical and clinical stages that you should keep an eye out ...

Also, when restricting the analysis to proliferation-related manufacturing failures, CH mutations were detected in 4/8 cases (50%) compared to 19/41 (46%) cases of successful production. No ...

The remarkable clinical success of CAR T therapies in blood cancers has validated the promise of engineered cell therapies. But according to Adam Janvier, PhD, head of cell therapy at eXmoor Pharma, ...

As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...

Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a ...

In-body manufacturing promises a faster, cheaper and simpler alternative to CAR-T cell therapy — if the field can deliver clinical readouts that prove long-term safety and efficacy. In vivo chimeric ...

T, has transformed treatment for blood cancers. The immunotherapy involves reprogramming a patient's own immune cells to ...

Researchers have engineered CAR-T cells armed with computationally designed protein binders that eliminated glioblastoma ...

"EHA26: AvenCell’s AVC-201-01 switchable allogeneic CAR T offers early validation in AML" was originally created and ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...